StockIQStockIQ.tech

Waters Corporation (WAT) Stock Analysis

--

Free AI-powered analysis and research for Waters Corporation stock

Sector: Healthcare

WAT snapshot

Data as of 4 Nov 2026 close. Updated daily.

Last close
470.09 USD (+2.22%)
52-week range
282.77 – 482.28
Position in range
94%
1-year change
+28.0%
Market cap (USD)
$46.2B
P/E (trailing)
118.6
RSI (14-day)
61
vs 200-day average
+26.9%
MACD
Above signal line
StockIQ score: 66/100 · Positive signals

Waters Corporation scores 66/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 94% of its 52-week range, up 28.0% over the past year. Latest reported figures show a profit margin of 3.6%, return on equity of 1.9% and revenue growth of +113.4%.

What is driving the score
  • Strong Uptrend: +12
  • MACD Bullish: +8
  • High P/E (118.6): -10
  • Strong Revenue Growth (113.4%): +8
  • Weak Profit Margin (3.6%): -8
  • Weak ROE (1.9%): -6
  • Strong Long-term Uptrend: +8
  • Healthy Momentum (+28.0% over 1 year): +7
  • Low Volume (0.4x): -3

Automated, general information only – not financial advice. Scores can be wrong. How the score works

Full WAT report

Waters Corporation (WAT) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.

Analyze WAT Now →

📰 Latest Update

Waters Q3 Earnings Call Highlights

Waters (NYSE: WAT) reported third-quarter 2026 revenue of $1.767 billion and adjusted earnings per share of $4.10, driven by double-digit organic growth and improved performance in acquired businesses. The Analytical Sciences Division generated $703 million in revenue, with significant growth in China and India, while the Biosciences Division saw a 2% increase to $396 million. The company also announced the acquisition of MOBILion Systems and highlighted ongoing AI initiatives to enhance its product offerings.

Read full article →

History

People also watch

TMO
Thermo Fisher Scientific Inc.
--
LLY
Eli Lilly and Company
--
ELV
Elevance Health Inc.
--
ENOV
Enovis Corporation
--
BNTC
Benitec Biopharma Inc.
--